Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase
被引:30
作者:
Takiguchi, Shunichi
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Dept Internal Med, Div Cardiol, Tokorozawa, Saitama, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Takiguchi, Shunichi
[1
,2
]
Ayaori, Makoto
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Ayaori, Makoto
[1
]
Uto-Kondo, Harumi
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Uto-Kondo, Harumi
[1
]
Iizuka, Maki
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Iizuka, Maki
[1
]
Sasaki, Makoto
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Sasaki, Makoto
[1
]
Komatsu, Tomohiro
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Komatsu, Tomohiro
[1
]
Takase, Bonpei
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Crit Care Med, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Takase, Bonpei
[3
]
Adachi, Tetsuo
论文数: 0引用数: 0
h-index: 0
机构:
Gifu Pharmaceut Univ, Lab Clin Pharmaceut, Tokorozawa, Saitama, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Adachi, Tetsuo
[4
]
Ohsuzu, Fumitaka
论文数: 0引用数: 0
h-index: 0
机构:
Dept Internal Med, Div Cardiol, Tokorozawa, Saitama, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Ohsuzu, Fumitaka
[2
]
Ikewaki, Katsunori
论文数: 0引用数: 0
h-index: 0
机构:
Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, JapanNatl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
Ikewaki, Katsunori
[1
]
机构:
[1] Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
[2] Dept Internal Med, Div Cardiol, Tokorozawa, Saitama, Japan
[3] Natl Def Med Coll, Dept Crit Care Med, Tokorozawa, Saitama 3598513, Japan
[4] Gifu Pharmaceut Univ, Lab Clin Pharmaceut, Tokorozawa, Saitama, Japan
Endothelial dysfunction in essential hypertension is an independent predictor for future cardiovascular events. Although inhibition of the renin-angiotensin system (RAS) reportedly improves endothelial function through its effects on oxidative stress and inflammation, questions remain regarding the factors that are pivotal for improvement of endothelial function by RAS inhibition. We therefore performed a prospective, randomized crossover trial in which an angiotensin II type 1 receptor antagonist, olmesartan and calcium channel blocker, amlodipine, were compared in 31 essential hypertensive patients. Results showed that, although both treatments achieved comparable lowering of blood pressure (BP), olmesartan, but not amlodipine, significantly improved endothelial function as evaluated by flow-mediated vasodilation (FMD) in the brachial artery. Although no significant changes in diabetic and lipid parameters were observed with either drug, olmesartan slightly decreased estimated glomerular filtration rate, which, surprisingly, translated into decreased microalbuminuria. In a similar vein, olmesartan reduced serum C-reactive protein and increased urine antioxidant levels compared with baseline, and reduced urine 8-epi-prostaglandin F2 alpha levels compared with both baseline and amlodipine. Finally, although overall changes in plasma extracellular superoxide dismutase (EC-SOD) levels were not modulated by either treatment, for olmesartan there was a positive correlation between changes in FMD and those in EC-SOD levels. In conclusion, olmesartan improved endothelial function in hypertensive patients independent of its BP-lowering effect, which was due, at least in part, to its antioxidative property. Therefore, olmesartan might provide a greater long-term benefit for hypertensive patients with impaired endothelial function than amlodipine. Hypertension Research (2011) 34, 686-692; doi: 10.1038/hr.2011.11; published online 10 February 2011